Skip to main content

Table 3 Clinical characteristics according to overall therapeutic response, as measured by neurodevelopment tests

From: Neuroregenerative potential of intravenous G-CSF and autologous peripheral blood stem cells in children with cerebral palsy: a randomized, double-blind, cross-over study

 

Total (number or mean ± SD)

Responder (N = 20)a

Non-responder (N = 27)

p

Sex

   

0.915

 Male

25

11

14

 

 Female

22

9

13

 

Age (years)

4.1 ± 1.9

3.2 ± 1.5

4.7 ± 1.9

0.968

Body weight (kg)

16.6 ± 7.70

13. 8 ± 2.57

18.5 ± 9.35

0.142

Infused TNC (×108/kg)

5.2 ± 2.54

5.7 ± 1.52

4.8 ± 3.04

0.847

CP type

   

0.215

 Diplegia

25

10

15

 

 Non-diplegia

22

10

12

 

Infusion time

   

0.028

 T1

22

5

17

 

 T7

25

15

10

 
  1. CP cerebral palsy; T1 and T7 refer to a group who received mobilized peripheral blood mononuclear cell at 1 and 7 months of study, respectively
  2. aResponder refers to a patient showing overall improvement at M13 as measured by neurodevelopment tests